FWM
CTXR icon

Focused Wealth Management’s Citius Pharmaceuticals CTXR Stock Holding History

Focused Wealth Management’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-11
Closed -$204 – 361
2023
Q4 		$204 Hold
11
– – ﹤0.01% 957
2023
Q3 		$185 Hold
11
– – ﹤0.01% 965
2023
Q2 		$324 Hold
11
– – ﹤0.01% 986
2023
Q1 		$316 Hold
11
– – ﹤0.01% 967
2022
Q4 		$213 Hold
11
– – ﹤0.01% 1013
2022
Q3 		$0 Hold
11
– – ﹤0.01% 962
2022
Q2 		$0 Hold
11
– – ﹤0.01% 951
2022
Q1 		$0 Buy
+11
New +$434 ﹤0.01% 1007

Other funds holding CTXR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Focused Wealth Management's CTXR Position: Q1 2024 in Review

Focused Wealth Management sold out of Citius Pharmaceuticals (CTXR) in Q1 2024, closing a stake of 11 shares — an estimated $204 sold.

Focused Wealth Management first reported a position in CTXR in Q1 2022 and held it in 8 quarters. The position peaked at $324 in Q2 2023. 73 funds tracked by Wall St. Rank hold CTXR as of Q1 2024.

  • Focused Wealth Management reported no remaining Citius Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Focused Wealth Management sold 11 Citius Pharmaceuticals shares in Q1 2024, an estimated $204.
  • Focused Wealth Management first reported a position in Citius Pharmaceuticals in Q1 2022 and held it in 8 quarters.
  • Focused Wealth Management's Citius Pharmaceuticals position peaked at $324 in Q2 2023.
  • 73 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2024.

Based on Focused Wealth Management's 13F filing for Q1 2024, filed 8 May 2024.